PKC412 Normalizes Mutation-related Keratin Filament Disruption and Hepatic Injury in Mice by Promoting Keratin-myosin Binding

Overview

Journal Hepatology

Specialty Gastroenterology

Date 2015 Jul 2

PMID 26126491

Citations 15

Authors

Raymond Kwan

Lu Chen

Koksun Looi

Guo-Zhong Tao

Sujith V Weerasinghe

Natasha T Snider

Mary Anne Conti

Robert S Adelstein

Qing Xie

M Bishr Omary

Affiliations

Soon will be listed here.

Abstract

Unlabelled: Keratins, among other cytoskeletal intermediate filament proteins, are mutated at a highly conserved arginine with consequent severe disease phenotypes due to disruption of keratin filament organization. We screened a kinase inhibitor library, using A549 cells that are transduced with a lentivirus keratin 18 (K18) construct, to identify compounds that normalize filament disruption due to K18 Arg90Cys mutation at the conserved arginine. High-throughput screening showed that PKC412, a multikinase inhibitor, ameliorated K18 Arg90Cys-mediated keratin filament disruption in cells and in the livers of previously described transgenic mice that overexpress K18 Arg90Cys. Furthermore, PKC412 protected cultured A549 cells that express mutant or wild-type K18 and mouse livers of the K18 Arg90Cys-overexpressing transgenic mice from Fas-induced apoptosis. Proteomic analysis of proteins that associated with keratins after exposure of K18-expressing A549 cells to PKC412 showed that nonmuscle myosin heavy chain-IIA (NMHC-IIA) partitions with the keratin fraction. The nonmuscle myosin-IIA (NM-IIA) association with keratins was confirmed by immune staining and by coimmunoprecipitation. The keratin-myosin association is myosin dephosphorylation-dependent; occurs with K8, the obligate K18 partner; is enhanced by PKC412 in cells and mouse liver; and is blocked by hyperphosphorylation conditions in cultured cells and mouse liver. Furthermore, NMHC-IIA knockdown inhibits PKC412-mediated normalization of K18 R90C filaments.

Conclusion: The inhibitor PKC412 normalizes K18 Arg90Cys mutation-induced filament disruption and disorganization by enhancing keratin association with NM-IIA in a myosin dephosphorylation-regulated manner. Targeting of intermediate filament disorganization by compounds that alter keratin interaction with their associated proteins offers a potential novel therapeutic approach for keratin and possibly other intermediate filament protein-associated diseases.

Citing Articles

Pathological Mechanisms Involved in Epidermolysis Bullosa Simplex: Current Knowledge and Therapeutic Perspectives.

Bchetnia M, Powell J, McCuaig C, Boucher-Lafleur A, Morin C, Dupere A Int J Mol Sci. 2024; 25(17).

PMID: 39273442 PMC: 11394917. DOI: 10.3390/ijms25179495.

Deacetylation via SIRT2 prevents keratin-mutation-associated injury and keratin aggregation.

Sun J, Li P, Gui H, Rittie L, Lombard D, Rietscher K JCI Insight. 2023; 8(14).

PMID: 37485877 PMC: 10443796. DOI: 10.1172/jci.insight.166314.

A cell-based drug discovery assay identifies inhibition of cell stress responses as a new approach to treatment of epidermolysis bullosa simplex.

Tan T, Common J, Lim J, Badowski C, Firdaus M, Leonardi S J Cell Sci. 2021; 134(19).

PMID: 34643242 PMC: 8542385. DOI: 10.1242/jcs.258409.

The EMT transcription factor Snai1 maintains myocardial wall integrity by repressing intermediate filament gene expression.

Gentile A, Bensimon-Brito A, Priya R, Maischein H, Piesker J, Guenther S Elife. 2021; 10.

PMID: 34152269 PMC: 8216718. DOI: 10.7554/eLife.66143.

Cytoskeletal control of early mammalian development.

Lim H, Plachta N Nat Rev Mol Cell Biol. 2021; 22(8):548-562.

PMID: 33927361 DOI: 10.1038/s41580-021-00363-9.

References

Snider N, Omary M . Post-translational modifications of intermediate filament proteins: mechanisms and functions. Nat Rev Mol Cell Biol. 2014; 15(3):163-77. PMC: 4079540. DOI: 10.1038/nrm3753. View

Wu W, Iwata S, Homma S, Worman H, Muchir A . Depletion of extracellular signal-regulated kinase 1 in mice with cardiomyopathy caused by lamin A/C gene mutation partially prevents pathology before isoenzyme activation. Hum Mol Genet. 2013; 23(1):1-11. PMC: 3857940. DOI: 10.1093/hmg/ddt387. View

Ku N, Soetikno R, Omary M . Keratin mutation in transgenic mice predisposes to Fas but not TNF-induced apoptosis and massive liver injury. Hepatology. 2003; 37(5):1006-14. DOI: 10.1053/jhep.2003.50181. View

Jazwinska A, Ehler E, Hughes S . Intermediate filament-co-localized molecules with myosin heavy chain epitopes define distinct cellular domains in hair follicles and epidermis. BMC Cell Biol. 2003; 4:10. PMC: 194435. DOI: 10.1186/1471-2121-4-10. View

Meyer T, Regenass U, Fabbro D, Alteri E, Rosel J, Muller M . A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity. Int J Cancer. 1989; 43(5):851-6. DOI: 10.1002/ijc.2910430519. View

Fuchs E, Weber K . Intermediate filaments: structure, dynamics, function, and disease. Annu Rev Biochem. 1994; 63:345-82. DOI: 10.1146/annurev.bi.63.070194.002021. View

Baribault H, Penner J, Iozzo R . Colorectal hyperplasia and inflammation in keratin 8-deficient FVB/N mice. Genes Dev. 1994; 8(24):2964-73. DOI: 10.1101/gad.8.24.2964. View

Ku N, Michie S, Oshima R, Omary M . Chronic hepatitis, hepatocyte fragility, and increased soluble phosphoglycokeratins in transgenic mice expressing a keratin 18 conserved arginine mutant. J Cell Biol. 1995; 131(5):1303-14. PMC: 2120631. DOI: 10.1083/jcb.131.5.1303. View

Coulombe P, Omary M . 'Hard' and 'soft' principles defining the structure, function and regulation of keratin intermediate filaments. Curr Opin Cell Biol. 2002; 14(1):110-22. DOI: 10.1016/s0955-0674(01)00301-5. View

10.

Kerns M, DePianto D, Dinkova-Kostova A, Talalay P, Coulombe P . Reprogramming of keratin biosynthesis by sulforaphane restores skin integrity in epidermolysis bullosa simplex. Proc Natl Acad Sci U S A. 2007; 104(36):14460-5. PMC: 1964870. DOI: 10.1073/pnas.0706486104. View

11.

Szeverenyi I, Cassidy A, Chung C, Lee B, Common J, Ogg S . The Human Intermediate Filament Database: comprehensive information on a gene family involved in many human diseases. Hum Mutat. 2007; 29(3):351-60. DOI: 10.1002/humu.20652. View

12.

Reagan-Shaw S, Nihal M, Ahmad N . Dose translation from animal to human studies revisited. FASEB J. 2007; 22(3):659-61. DOI: 10.1096/fj.07-9574LSF. View

13.

Tao G, Li D, Zhou Q, Toivola D, Strnad P, Sandesara N . Monitoring of epithelial cell caspase activation via detection of durable keratin fragment formation. J Pathol. 2008; 215(2):164-74. DOI: 10.1002/path.2344. View

14.

Omary M . "IF-pathies": a broad spectrum of intermediate filament-associated diseases. J Clin Invest. 2009; 119(7):1756-62. PMC: 2701889. DOI: 10.1172/JCI39894. View

15.

Coulombe P, Kerns M, Fuchs E . Epidermolysis bullosa simplex: a paradigm for disorders of tissue fragility. J Clin Invest. 2009; 119(7):1784-93. PMC: 2701872. DOI: 10.1172/JCI38177. View

16.

Omary M, Ku N, Strnad P, Hanada S . Toward unraveling the complexity of simple epithelial keratins in human disease. J Clin Invest. 2009; 119(7):1794-805. PMC: 2701867. DOI: 10.1172/JCI37762. View

17.

Sanz M, Burnett A, Lo-Coco F, Lowenberg B . FLT3 inhibition as a targeted therapy for acute myeloid leukemia. Curr Opin Oncol. 2009; 21(6):594-600. DOI: 10.1097/CCO.0b013e32833118fd. View

18.

Gani O, Engh R . Protein kinase inhibition of clinically important staurosporine analogues. Nat Prod Rep. 2010; 27(4):489-98. DOI: 10.1039/b923848b. View

19.

Wu W, Shan J, Bonne G, Worman H, Muchir A . Pharmacological inhibition of c-Jun N-terminal kinase signaling prevents cardiomyopathy caused by mutation in LMNA gene. Biochim Biophys Acta. 2010; 1802(7-8):632-8. PMC: 2893287. DOI: 10.1016/j.bbadis.2010.04.001. View

20.

Fischer T, Stone R, DeAngelo D, Galinsky I, Estey E, Lanza C . Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol. 2010; 28(28):4339-45. PMC: 4135183. DOI: 10.1200/JCO.2010.28.9678. View